2008-2021: U.S. new drug listing prices rose nearly 90 times
- FDA Approved Opdualag: The First Immunotherapy Targeting LAG-3
- Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Evidence
- Brief Intermittent Exercise Reduces Heart Disease and Death Risk
- Personalized Lung Tumor Chips Assess PD-1 Therapy Response
- Study Shows Prior Infection Offers Strong Immunity to Original COVID-19 Strain
- Chinese Food Products Dominate Korean Tables Amid Safety Concerns
2008-2021: U.S. new drug listing prices rose nearly 90 times
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
2008-2021: U.S. new drug listing prices rose nearly 90 times
On June 7, Harvard Medical School professors Aaron S. Kesselheim, Benjamin N. Rome and assistant researcher Alexander C. Egilman published “Trends in Prescription Drug Launch Prices, 2008-2021” article.
A total of 548 (95%) of the 576 drugs that were first marketed between 2008 and 2021 were included in the study, 3 diagnostic drugs and 25 drugs for which annual prices could not be estimated were excluded.
Of these, 357 (65%) were new molecular entities, 139 (25%) were biologics, 182 (33%) were rare disease drugs, 64 (12%) were marketed through the accelerated approval pathway, 119 (22%) were %) is a tumor drug.
The most expensive drugs are rare disease drugs and oncology drugs, with a median price of $168,441/year and $155,091/year, respectively.
Statistics found that from 2008 to 2021, the annual growth rate of new drug listing prices was 20.4%, adjusted according to drug characteristics, 13%, and the annual growth rate of net prices was 10.7%.
The median price has increased from $2,115/yuan in 2008 to $180,007/year in 2021. The proportion of drugs priced above $150,000/year was 9% (18/197) in 2008-2013 and 47% (42/89) in 2020-2021.
The median net price has increased from $1,376/year in 2008 to $159,042/year in 2021.
The article said that new drug price growth trends outpaced other medical services, and that manufacturers routinely raise prices over time after a drug is on the market.
In response to current trends, the U.S. could stop allowing drug makers to set prices freely and follow other industrialized nations in negotiating drug prices when they come to market.
2008-2021: U.S. new drug listing prices rose nearly 90 times
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.